Literature DB >> 11172539

Effects of the acute myeloid leukemia--associated fusion proteins on nuclear architecture.

M Faretta1, L Di Croce, P G Pelicci.   

Abstract

Acute myeloid leukemias (AMLs) are consistently associated with chromosomal rearrangements that result in the generation of chimeric genes and fusion proteins. One of the two affected genes is frequently a transcription factor Involved in the regulation of hematopoletic differentiation. Recent findings suggest a common leukemogenic mechanism for the fused transcription factor: abnormal recruitment of histone deacetylase (HDAC)-containing complexes to its target promoters. Inhibition of HDAC enzymatic activity reverts the leukemic phenotype in vitro and therefore represents a plausible strategy for antileukemic therapy. In this review, we first briefly describe the molecular structure and mechanisms of the most frequent AML associated fusion proteins (RAR, MLL, and CBF fusions) and then summarize available knowledge about their effects on the nuclear architecture. We propose that alteration of nuclear compartmentalization might represent an additional common mechanism of leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172539     DOI: 10.1016/s0037-1963(01)90005-8

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  3 in total

1.  Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas.

Authors:  Y Murakami; K Saigo; H Takashima; M Minami; T Okanoue; C Bréchot; P Paterlini-Bréchot
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

2.  Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.

Authors:  Anas Younes; Yasuhiro Oki; R Gregory Bociek; John Kuruvilla; Michelle Fanale; Sattva Neelapu; Amanda Copeland; Daniela Buglio; Ahmed Galal; Jeffrey Besterman; Zuomei Li; Michel Drouin; Tracy Patterson; M Renee Ward; Jessica K Paulus; Yuan Ji; L Jeffrey Medeiros; Robert E Martell
Journal:  Lancet Oncol       Date:  2011-10-25       Impact factor: 41.316

3.  Point mutation in AML1 disrupts subnuclear targeting, prevents myeloid differentiation, and effects a transformation-like phenotype.

Authors:  Diana Vradii; Sayyed K Zaidi; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.